カテゴリ： GlobalData, アメリカ, 企業調査

CymaBay Therapeutics Inc (CBAY)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：CymaBay Therapeutics Inc (CBAY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9775
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：56
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Arhalofenate, an oral small molecule intended for the treatment of Gout flares. It also develops MBX-2982 and MBX-8025 for patients with type 2 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

CymaBay Therapeutics Inc (CBAY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11
Partnerships 12
HistoIndex and CymaBay Therapeutics Enter into Partnership 12
Equity Offering 13
CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13
CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15
CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17
CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18
CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19
CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21
CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For US$33.2 Million 23
CymaBay Therapeutics Inc – Key Competitors 24
CymaBay Therapeutics Inc – Key Employees 25
CymaBay Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Nov 06, 2018: CymaBay reports third quarter 2018 financial results and provides corporate update 27
Nov 06, 2018: Cymabay reports third quarter 2018 financial results and provides corporate update 29
Aug 09, 2018: Cymabay reports second quarter 2018 financial results and provides corporate update 31
May 08, 2018: CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 15, 2018: CymaBay Announces Fourth Quarter and Fiscal 2017 Financial Results 34
Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates 36
Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 23, 2017: CymaBay Reports Fourth Quarter and Year End 2016 Financial Results 40
Corporate Communications 41
Mar 29, 2017: CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. 41
Product News 42
10/31/2017: CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer 42
06/19/2018: CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018 43
01/08/2018: CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis 44
01/08/2018: CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America 45
Product Approvals 46
Sep 11, 2017: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis 46
Clinical Trials 47
May 08, 2018: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis 47
Apr 11, 2018: CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 48
Oct 23, 2017: CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis 50
Oct 09, 2017: CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting 51
Aug 15, 2017: CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology 52
Jul 17, 2017: CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis 53
Apr 13, 2017: CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 54
Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11
HistoIndex and CymaBay Therapeutics Enter into Partnership 12
CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13
CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15
CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17
CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18
CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19
CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21
CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For US$33.2 Million 23
CymaBay Therapeutics Inc, Key Competitors 24
CymaBay Therapeutics Inc, Key Employees 25

List of Figures
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CymaBay Therapeutics Inc (CBAY)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Autoliv Inc (ALV)：企業の財務・戦略的SWOT分析
    Autoliv Inc (ALV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Statoil ASA (STL)-石油・ガス分野：企業M&A・提携分析
    Summary Statoil ASA (Statoil) is an independent upstream oil and gas company. The company explores for, develops and produces oil and gas from its assets across the world, and trades crude oil and natural gas. The company operates assets in Norwegian Continental Shelf (NCS), which includes the North …
  • Petrobras Argentina SA：企業の戦略的SWOT分析
    Petrobras Argentina SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Asian Infrastructure Investment Bank：電力：M&Aディール及び事業提携情報
    Summary Asian Infrastructure Investment Bank (AIIB) is a multilateral financial institution. The company develops infrastructure and other productive sectors. It provides sovereign and non-sovereign finance for sustainable projects in energy and power, transportation and telecommunications, rural in …
  • W.H. Brakspear & Sons Limited：企業の戦略・SWOT・財務情報
    W.H. Brakspear & Sons Limited - Strategy, SWOT and Corporate Finance Report Summary W.H. Brakspear & Sons Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Molnlycke Health Care AB：企業の戦略的SWOT分析
    Molnlycke Health Care AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • The Nassau Companies of New York：企業の戦略的SWOT分析
    The Nassau Companies of New York - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • DAMAC Real Estate Development Ltd：企業の戦略・SWOT・財務情報
    DAMAC Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary DAMAC Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Foundation Medicine Inc (FMI)：企業の財務・戦略的SWOT分析
    Summary Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd, is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne …
  • Oceaneering International Inc (OII)：企業の財務・戦略的SWOT分析
    Oceaneering International Inc (OII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • OCI Co Ltd (010060)：電力：M&Aディール及び事業提携情報
    Summary OCI Co Ltd (OCI) is a green energy and chemical company. It manufactures and sells a wide range of inorganic chemicals, coal and petrochemicals, and fine chemicals. The company’s product portfolio includes toluene di-isocyanate (TDI), hydrogen peroxide, carbon black, pitch, sodium percarbona …
  • At Home Group Inc. (HOME)：企業の財務・戦略的SWOT分析
    At Home Group Inc. (HOME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cabot Oil & Gas Corp (COG)：企業の財務・戦略的SWOT分析
    Cabot Oil & Gas Corp (COG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • First Republic Bank：企業の戦略・SWOT・財務情報
    First Republic Bank - Strategy, SWOT and Corporate Finance Report Summary First Republic Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • First Pacific Co Ltd (142)：企業の財務・戦略的SWOT分析
    First Pacific Co Ltd (142) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NII Holdings Inc (NIHD)：企業の財務・戦略的SWOT分析
    Summary NII Holdings Inc (NII Holdings) is a mobile communication service provider that offers communication products and services. The company offers solutions such as 3G mobile broadband services, content downloads and messaging. It also provides digital cellular voice services, data services, and …
  • Serina Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Serina Therapeutics Inc (Serina Therapeutics) is a drug company that develops therapeutics for cancer, inflammation, pain, and metabolic disorders. The company’s pipeline product includes SER-214, SER-226, SER-228, SER-232, and other proprietary drugs. It uses proprietary technology, polyoxa …
  • Nephros Inc (NEPH)：企業の財務・戦略的SWOT分析
    Summary Nephros Inc (Nephros) is dialysis device manufacturer. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters includes Endotoxin ten Cartridge filter, SSUmini, DSU-D and SSU-D. Nephros dialysis ultrafilters are intended …
  • Helomics Corp-医療機器分野：企業M&A・提携分析
    Summary Helomics Corp(Helomics) is a life science company that develops and offers precision medicine support tools and services for cancer treatment. The company’s products include chemofx, biospecifx, genefx colon and genefx lung. Its chemofx is a drug response marker, which is used to test tumor …
  • Fufeng Group Limited：企業の戦略・SWOT・財務情報
    Fufeng Group Limited - Strategy, SWOT and Corporate Finance Report Summary Fufeng Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆